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Introduction
Tumors of the central nervous system  (CNS)
constitute a small fraction of the overall human can-
cers. However, their incidence is continually increasing
and among children they take the second place just
after leukemia. Gliomas represent a group of neo-
plasms derived from neuroepithelial tissue. Histologi-
cally, they are classified into four groups ranging from
I (benign) to IV (glioblastoma) and the treatment de-
pends on pathological diagnosis. Glioma arises in all
age groups, however, low-grade tumors occur pre-
dominantly in children and high-grade ones in elderly
people. Despite being characterized by a high invasive
activity, glioma is rarely metastatic outside the CNS,
indicating a successful regional prognosis and treat-
ment of the patients (1’ 2). 
Neuroblastoma (NB) is the most frequent solid
extracranial malignancy in children and a major cause
of death from cancer in infancy. It consists of neural
crest derived from undifferentiated neuroectodermal
cells. Tumor stage and patient age at diagnosis corre-
late strongly with survival. NB can form relatively
benign, localized and well-differentiated tumors that
are successfully treated by surgical resection alone
(stage I or II) or locally invasive (stage III) and metasta-
tic (stage IV) tumors associated with a fatal clinical out-
come. Many NB present at diagnosis with metastatic
disease are usually associated with poor survival
despite intensive therapy (3’ 4). 
Angiogenesis is essential for tumor growth and
relies on the production of angiogenic factors. It has
become generally accepted that solid tumors have to
develop a vascular system for nutrient delivery and
waste removal in order to grow appreciably (5). This
process, angiogenesis, is critical to the progression of
brain tumors, with vascular changes accompanying
the advancement of these tumors. The cascade of
events in this process of blood vessel formation in-
volves a complex interplay between tumor cells, en-
dothelial cells and their surrounding basement mem-
branes (6’7).
In the present study, the contribution of angio-
genic growth factors-vascular endothelial growth fac-
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Summary: Angiogenesis is essential for tumor growth and relies on the production of angiogenic factors.
By comparative analysis using RT-PCR method of angiogenic growth factors: VEGF, bFGF, PDGF-A, angiogenin-
1 and IL-8 we established the level of expression of these genes necessary for angiogenesis in glioma and neu-
roblastoma cell lines. Our analyses were also extended to CD44 gene, which plays an important role in cascade
of metastasis and progression of brain tumors. Significant differences in the level of gene expression of angio-
genic factors and CD44 gene between the two cell lines observed throughout this study can be used as a prog-
nostic marker for predicting clinical outcome in human brain tumors at the time of the initial staging.
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tor (VEGF165), basic fibroblast growth factors (bFGF),
platelet-derived growth factor-A (PDGF-A), angioge-
nin-1 (Ang-1) and interleucin-8 (IL-8) ’ to glioma and
NB was examined. These growth factors may influ-
ence glioma and NB angiogenesis by directly stimu-
lating endothelial cell proliferation, by mediating the
expression of key proteases on endothelial cells ne-
cessary for angiogenesis, or by regulating the expre-
ssion of VEGF and other relevant genes. Although, the
biological mechanisms that underlie the clinical vari-
ability observed in glioma and NB including tumor
stage, patient age, histology, molecular markers, me-
tastatic insemination etc., it has been shown that an-
giogenesis remains largely unknown in the regulation
of brain tumors (8’11).
In this work, we extended our analyses to de-
monstrate the correlation between the expression of
CD44 gene and that of different angiogenic factors
involved in tumor angiogenesis and development of
metastatic phenotype. The cell adhesion glycoprotein
CD44 is a polymorphic molecule resulting from alter-
native splicing. It plays an important role in cascade of
metastasis and progression of human malignant tu-
mors. The analysis of CD44 gene expression in human
malignant tissues has been shown to display a strong
association with striking differences between metasta-
tic and non-metastatic prognostic value (12’14).
The aim of this study was to develop a rapid
method using RT-PCR for detection of different angio-
genic factors and CD44 gene expression as a prog-
nostic marker for predicting clinical outcome in
human brain tumors at the time of initial staging.
Moreover, the understanding of the basic mechanisms
involved in brain tumor angigenesis could lead to
development of angiogenesis-inhibiting factors as
novel anti-tumor agents with a number of advantages
over conventional chemotherapeutics.
Material and Methods
Cells and culture conditions
Human glioma cell lines U-87 MG (HTB-14) and
neuroblastoma SK-N-SH (HTB-11) were obtained
from American Type Culture Collection (ATCC,
Rockville, U.S.A.) and only low passage cell lines were
used. Both cell lines were maintained as monolayer
cultures in Eagle's Minimal Essential medium with
Earle's BSS and 2 mmol/L L-glutamine EMEM con-
taining 10% fetal bovine serum (Sigma, Germany) and
1 mmol/L sodium pyruvate, 0.1 mmol/L nonessential
amino acids, 1.5 g/L sodium bicarbonate (Sigma,
Germany) at 37 ‰C and 5% CO2 ’ 95% air-atmosphere
in humidified incubator. The cells harvested in tryp-
sin/EDTA solution in PBS and double washed in PBS
were ready for the isolation of total RNA.
RNA isolation and reverse transcription (RT)
Total RNA was isolated from 5×106 cells by
Qiagen RNAeasy total RNA preparation kit (Germany)
according to the manufacturer's instruction. After pu-
rification and washing, the RNA was eluted with 50 mL
DEPC-treated water. The purity and yield of the total
RNA were determined spectrophotometrically and its
integrity checked by agarose gel electrophoresis.
For the synthesis of cDNAs, 1 mg of total RNA
was reverse transcribed in RT buffer (containing 50
mmol/L KCl, 10 mmol/L Tris-HCl, pH 8.3, 5 mmol/L
MgCl2), 100 mmol/L DTT, 2.5 mmol/L Oligo (dT)16,
dNTPs 0.5 mmol/L each, 1 U RNase inhibitor and 2.5
U murine leukemia virus reverse transcriptase (MuLV
RT) in a final volume of 10 mL (Gibco-BRL, U.S.A).
The reaction cycle consisted of 1 h at 42 ‰C, 10 min at
95 ‰C and cooling to 5 ‰C. The cDNAs were kept at
’20 ‰C. To minimize errors in pipetting among the
samples, master mixes of cDNA synthesis buffer con-
taining dNTPs, RT buffer, oligo(dT), DTT and the
enzymes were prepared and used for RT of all RNA
samples in experiment.
PCR assay
For PCR amplification, appropriate dilutions of
cDNA samples representing 100 ’200 ng of total RNA
were mixed with PCR buffer containing 100 mmol/L
dNTPs, 1.5 mmol/L MgCl2, 10 × Stoffel Buffer (con-
taining 50 mmol/L KCl and 10 mmol/L Tris-HCl),
0.8’1 mmol/L each of the primers and 1.25 U Stoffel
Taq polymerase in a total volume of 25 mL (Perkin-
Elmer, U.S.A). 
A PCR primer pair for angiogenic growth factors
and CD44 sequences obtained from Gene Bank, were
used to design the primer pairs. All oligonucleotide
primer pairs spanned the intron/exon splice site,
ensuring that PCR products did not arise from DNA
contamination present in the RNA preparations. The
amplification products were normalized against the
»housekeeping« gene GAPDH and cyclophilin (p1B15).
The primer sequences and PCR product size are pre-
sented in Table I (15).
For the CD44 and IL-8 gene amplification cycle
parameter was as follows: 55 ‰C for 8 min, 30 cycles
at 94 ‰C for 1 min, 55 ‰C for 1 min, 72 ‰C for 1 min
and the final cycle 72 ‰C for 8 min. For the rest of the
samples: VEGF, bFGF, PDGF-A and angiogenin-1
cycle parameters in all cases were:  94 ‰C for 1 min, 61
‰C for 2 min and 72 ‰C for 2 min (30 cycles). PCR-
amplified products were analyzed by electrophoresis in
1.5% agarose gel. All PCRs were done at least five
times. The levels of CD44 mRNA were compared and
a correction was made for differences in GAPDH
mRNA. The levels of angiogenic growth factors
mRNAs were compared and corrected for p1B15
mRNA levels. The expression of the target gene was
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normalized by taking the ratio of the densitometric unit
of the gene/densitometric unit of internal control,
p1B15 or GAPDH. For the PCRs, relative signal inten-
sities were calculated and the data presented as the
mean “ SEM. 
Results
Since SK-N-SH and U-87 MG were shown to
secrete high amounts of VEGF (16’17), we selected
these tumor cell lines to study the level of expression
of some angiogenic factors such as: VEGF165, bFGF,
PDGF-A, IL-8 and Ang-1. In this study we also investi-
gated CD44 gene expression to confirm their metasta-
tic potential in tumorogensis of glioma and NB. 
To determine which angiogenic factors were
expressed predominantly in SK-N-SH and U-87 MG,
we analyzed the expression of the angiogenic mRNA in
human glioma and NB cell lines using semiquantita-
tive RT-PCR. Representative examples of RT-PCR pro-
ducts were separated by agarose gel electrophoresis
presented in Figure 1. It can be seen that mRNA of all
angiogenic factors and CD44 gene in SK-N-SH and U-
87 MG cell lines were detected by this method. Quan-
tification of mRNA expression was performed by den-
sitometric analysis of the gels and taking the ratio of
target gene and housekeeping gene as internal con-
trol-normalized target gene. The results are summa-
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Primer Sequence
5'-GGATGACTATCAGCGCAGCTAC-3'
5'-TCACCGCCTCGGCTTGTCACATC-3'
5'-CATCATGAGGAGACGGGG-3'
5'-TCCAAGTGGACAGGTAAGCC-3'
5'-ATGGCAGCCGGGAGCATCACC-3'
5'-CACACACTCCTTTGATAGACACAA-3'
5'-GAGTGAGGATTCTTTGGACACC-3'
5'-CTTCTTCCTGACGTATTCCACC-3'
5'-TTGGCAGCCTTCCTGATTTC-3'
5'-AACTTCTCCACAACCCTCCTG-3'
5'-GGATCCATGAGTGGTATGGGA-3'
5'-GAATTCACCGACAGCACAGACAGA-3'
5'-AGAAGCGCATGAGCATTGTGGAAG-3'
5'-TGCTCTCCTGAGCTACAGAAGGAA-3'
5'-CGGAGTCAACGGATTTGGTCGTAT-3'
5'-AGCCTTCTCCATGGTGGTGAAGAC-3'
Ta (‰C)
61
61
61
61
55
55
61
55
PCR product (bp)
454
264
239
322
247
480
159
306
cDNA
VEGF165
Sense
Antisense
Ang-1                       
Sense
Antisense
bFGF
Sense
Antisense
PDGF-A
Sense
Antisense
IL-8
Sense
Antisense
CD44
Sense
Antisense
P1B15
Sense
Antisense
GAPDH
Sense
Antisense 
Table I   Primer Sequences and Annealing Temperatures Used
Figure 1.   Expression of VEGF165, bFGF, PDGF-A, 
Ang-1, IL-8 and CD44 genes in human neuroblastoma 
SK-N-SH (A) and glioma U-87 MG (B) cell lines. 
The expression of angiogenic factors and CD44 was 
determined by RT-PCR. Total RNA was extracted from con-
fluent cultures as described under Materials and 
methods. The first strand cDNA was synthesized by reverse
transcription of total cellular RNA and PCR-amplified with
varying primer concentrations. RT-PCR products were 
subjected to electrophoresis in 1.5 % agarose gel, stained
with ethidium bromide and photographed under UV light.
Quantification was performed using Multi-Analyst/PC
Software Image Analysis System (BIO-Rad, Gel Doc 1000).
Panel A, neuroblastoma, SK-N-MC. Lanes: 1 ’ bFGF; 
2 ’ Ang-1; 3 ’ PDGF-A; 4 ’ VEGF165; 5 ’ IL-8 and 
6 ’ CD44. Panel B, glioma, U-87 MG. Lanes: Lanes: 
1 ’ bFGF; 2 ’ Ang-1; 3 ’ PDGF-A; 4 - VEGF165; 5 ’ IL-8
and 6 ’ CD44. M ’ molecular size markers.
Arrows indicate the position of housekeeping genes.
M    1     2    3     4            M     5    6
M    1     2    3     4            M     5    6
A
B
rized in Tables II and III. As shown in Table III, in U-
87 MG cell line VEGF165, Ang-1, bFGF, PDGF-A, IL-8
and CD44 were upregulated from 1.0’19-times more
than in SK-N-SH cell line (Table II). In this cell line, the
most prominent level of IL-8 mRNA expression was
detected. Although, the level of expression of bFGF,
PDGF-a and IL-8 mRNA was also highly upregulated
in SK-N-SH cell line, the difference between the two
cell lines was obvious and the expression of these
genes was from 3 ’19-fold increased in U-87 MG cell
line.
Discussion
Angiogenesis is essential for tumor growth and
metastases formation. Numerous angiogenic factors
that regulate this complex process alone or in synergy
have been identified. So, VEGF, bFGF, PDGF, Ang-1,
IL-8 etc. have been shown to induce angiogenesis in a
variety of experimental models (10, 18’19). 
Our results indicate that all five angiogenic fac-
tors examined here showed a broad expression pat-
tern in human glioma and NB cell lines suggesting
their involvement in angiogenesis of brain tumors
(20 ’21). VEGF is an important angiogenic factor and
endothelium-specific mitogen, which has been impli-
cated in the neovascularization of a wide variety of
tumors. It acts via a paracrine mechanism mainly
through two specific receptors at the surface of
endothelial cells (22’24). In our study both cell lines
exhibited a significantly low VEGF mRNA expression in
comparison with the other angiogenic factors. These
results are in agreement with our previous report
where we demonstrated that human glioma cell lines
responded to EGF with a higher stimulation of VEGF
secretion into the culture medium comparing to those
growing in EGF-free medium (16). For this reason, we
concluded that this result is in accordance with our
present finding demonstrating that VEGF165 mRNA
positively correlates with its protein expression as an
indicator of VEGF secretion of these cells without EGF
stimulation. 
The results obtained throughout the present
study clearly demonstrate that bFGF mRNA indicates
a relatively higher level of expression (3.8-fold) com-
paring to VEGF mRNA in glioma cell lines as deter-
mined by RT-PCR assay. The identification bFGF
mRNA in glioma cell lines tested is consistent with a
recent report that increased expression of bFGF is
associated with malignant progression of astrocytic
tumors (25). Relative expression of bFGF, as well as
the level and type of receptor expression may be key
determinants of the transformed state in tumors of
glial origin (1).
Angiogenin (Ang-1), the ligand for TIE-2, a re-
ceptor-like tyrosine kinase expressed in endothelial
cells, seems to be important to maintain blood vessels
integrity by mediating interactions between the
endothelium and surrounding matrix (26). Since it sta-
bilizes the structure of newly-formed blood vessels, it
takes part in the process of angiogenesis later than
VEGF. Expression levels of VEGF gene family, bFGF
and Ang-1 are correlated with each other in glioma
and NB tumors and besides, with a high degree of vas-
cularization suggesting their synergistic action in tu-
mor angiogenesis.
In the present study, we demonstrated several
time higher level of expression of IL-8 and PDGF-A
mRNAs in U-87 MG glioma cell lines than in SK-N-SH
in vitro. We found that such high expression levels
both of IL-8 and PDGF-A mRNAs correlated strongly
with advanced stage of malignancy. Their different
levels of expression in the two cell lines used in this
work suggest that different signal transduction path-
ways are included in the regulation of angiogenesis at
different levels (17). 
PDGF consists of two related polypeptides (a-
and b-chain) and it binds to two classes of the recep-
tors a- and b-receptors Endothelial cells may respond
to autocrine and paracrine PDGF-B through their b-
receptors whereas the a-receptors on glioma cells
proper may be activated by autocrine PDGF-A. It was
originally known to be involved in the regulation of cell
migration and proliferation, but more recently was
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n
3
3
3
3
3
3
x
± 0.339
± 0.259
± 0.355
± 0.404
± 1.683
± 0.197
d
0.177
0.011
0.146
0.329
0.461
0.146
CV (%)
13%
1%
14%
27%
9%
25%
VEGF
Ang-1
bFGF
PDGF
IL-8
CD44
The expression of the target gene was normalized by taking the
ratio of the densitometric unit of the gene/densitometric unit of
internal control, p1b15 or GAPDH.
Table II   Mean values of angiogenic factors and CD44
epression in neuroblastoma cell line SK-N-SH
n
3
3
3
3
3
3
x 
“ 0.264
“ 0.431
“ 0.828
“ 2.045
“ 8.456
“ 0.313
d
0.190
0.352
0.560
1.131
8.770
0.228
CV(%)
18%
20%
23%
18%
35%
24%
VEGF
Ang-1
bFGF
PDGF
IL-8
CD44
The expression of the target gene was normalized by taking the
ratio of the densitometric unit of the gene/densitometric unit of
internal control, p1b15 or GAPDH.
Table III   Mean values of angiogenic factors and CD44
expression in glioma cell line U-87 MG
reported to possess an angiogenic capability both in
vitro and in vivo (27). Our results demonstrated here
that the expression of PDGF-A was highly elevated in
both examined cell lines, especially in glioma, sug-
gesting that in glioma cells PFGF-A may play an
angiogenic or cell migrating rather than mitogenic
role.
In the present study, we found that the CD44
standard form was expressed in a relatively low level
comparing to the other angiogenic factors. Moderate
to low CD44 expression was detected in these two cell
lines indicating that CD44 expression did not appear
to be directly related to amplification and overexpres-
sion of the oncogenes, but rather to the morphologi-
cal cell type and lineage (28). 
In conclusion, further studies are necessary to
understand in detail biological significance of angio-
genesis inhibitors and activators, which directly affect
vascularity, tumor growth and metastasis. Taken
together, our results suggest that several angiogenic
factors play biological role in angiogenesis. They
might contribute synergistically to a more aggressive
angiogenic process targeting molecules for antiangio-
genic therapy providing novel strategy that may be
particularly useful for highly metastasic advanced sta-
ge tumors (29’30). More general antiangiogenic
approaches using synthetic small molecules, to inhib-
it endothelial proliferation independent on angiogenic
factor expression, might be more promising in brain
tumors therapy. 
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Kratak sadr`aj: Angiogeneza je neophodna za rast tumora i zahteva proizvodnju angiogenih trofi~kih fak-
tora koji u~estvuju u tumorogenezi. Uporednom analizom angiogenih trofi~kih faktora: VEGF, bFGF, PDGF-A,
angiogenina-1 i IL-8 pomo}u metode RT-PCR utvrdili smo nivo ekspresije ovih gena uklju~enih u proces angio-
geneze u }elijskim linijama glioma i neuroblastoma. Tako|e smo pro{irili analize i na CD44 gen koji igra va`nu
ulogu u kaskadi nastanka i progresiji metastaza tumora mozga. Dobijeni rezultati ukazuju na zna~ajnu razliku u
nivou genske ekspresije angiogenih faktora i CD44 gena u ove dve }elijske linije ~ije se poreklo razlikuje ne samo
po nastanku ve} i po mestu rasejavnja metastaza. Rezultati bi mogli da poslu`e kao prognosti~ki faktor u prekli-
ni~kim i klini~kim istra`ivanjima tumora mozga od inicijalnih do terminalnih stupnjeva nastanka i terapije.
Klju~ne re~i: angiogeni faktori rasta, CD44 gen, RT-PCR, glioma, neuroblastoma, ekspresija gena
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